PUBLISHER: TechNavio | PRODUCT CODE: 2172605
PUBLISHER: TechNavio | PRODUCT CODE: 2172605
Global Tetanus Toxoid Vaccine Market 2026-2030
The global tetanus toxoid vaccine market is forecasted to grow by USD 1539.7 mn during 2025-2030, accelerating at a CAGR of 5.1% during the forecast period. The report on the global tetanus toxoid vaccine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing maternal and neonatal tetanus prevention initiatives, expanding national immunization coverage across emerging economies, growing emphasis on lifelong vaccination among adult populations.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 4.6% |
| CAGR | 5.1% |
| Incremental Value | $1539.7 mn |
Technavio's global tetanus toxoid vaccine market is segmented as below:
By Age Group
- Neonatals
- Adults
By Drug Class
- Combination
- Monovalent tetanus toxoid
By End-User
- Hospitals
- Specialty clinics
- Public health agencies
- Ambulatory care centers
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the advancing adoption of combination vaccine formulations as one of the prime reasons driving the global tetanus toxoid vaccine market growth during the next few years. Also, increasing regional diversification of vaccine manufacturing networks and evolving digitalization of vaccine supply chain and cold chain monitoring will lead to sizable demand in the market.
The report on the global tetanus toxoid vaccine market covers the following areas:
- Global tetanus toxoid vaccine market sizing
- Global tetanus toxoid vaccine market forecast
- Global tetanus toxoid vaccine market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global tetanus toxoid vaccine market vendors that include AJ Vaccines AS, Bharat Biotech Ltd., BioKangtai, Biological E. Ltd., Daiichi Sankyo Co. Ltd., Dano Vaccines and Biologicals, GlaxoSmithKline Plc, Haffkine Bio Pharmaceutical, Incepta Vaccine Ltd., Indian Immunologicals Ltd., Institute of Vaccines and Medical, LG Chem Ltd., Microgen, Panacea Biotec Ltd., PT Bio Farma, Sanofi SA, Seasons Healthcare Ltd, Serum Institute of India Ltd., Sinovac Biotech Ltd.. Also, the global tetanus toxoid vaccine market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Age Group
- Executive Summary - Chart on Market Segmentation by Drug Class
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Tetanus Toxoid Vaccine Market 2020 - 2024
- Historic Market Size - Data Table on Global Tetanus Toxoid Vaccine Market 2020 - 2024 ($ million)
- 5.2 Age Group segment analysis 2020 - 2024
- Historic Market Size - Age Group Segment 2020 - 2024 ($ million)
- 5.3 Drug Class segment analysis 2020 - 2024
- Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
- 5.4 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on global tetanus toxoid vaccine market
- 6.2 Impact of geopolitical conflicts on global tetanus toxoid vaccine market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Age Group
- 8.1 Market segments
- 8.2 Comparison by Age Group
- 8.3 Neonatals - Market size and forecast 2025-2030
- 8.4 Adults - Market size and forecast 2025-2030
- 8.5 Market opportunity by Age Group
- Market opportunity by Age Group ($ million)
9 Market Segmentation by Drug Class
- 9.1 Market segments
- 9.2 Comparison by Drug Class
- 9.3 Combination - Market size and forecast 2025-2030
- 9.4 Monovalent tetanus toxoid - Market size and forecast 2025-2030
- 9.5 Market opportunity by Drug Class
- Market opportunity by Drug Class ($ million)
10 Market Segmentation by End-user
- 10.1 Market segments
- 10.2 Comparison by End-user
- 10.3 Hospitals - Market size and forecast 2025-2030
- 10.4 Specialty clinics - Market size and forecast 2025-2030
- 10.5 Public health agencies - Market size and forecast 2025-2030
- 10.6 Ambulatory care centers - Market size and forecast 2025-2030
- 10.7 Market opportunity by End-user
- Market opportunity by End-user ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 France - Market size and forecast 2025-2030
- 12.4.3 UK - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Colombia - Market size and forecast 2025-2030
- 12.6.7 South Africa - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Increasing maternal and neonatal tetanus prevention initiatives
- Expanding national immunization coverage across emerging economies
- Growing emphasis on lifelong vaccination among adult populations
- 13.2 Market challenges
- Stringent regulatory approval and batch release requirements
- Limited disease awareness in adult booster immunization programs
- Dependence on public procurement and immunization budget allocations
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Advancing adoption of combination vaccine formulations
- Increasing regional diversification of vaccine manufacturing networks
- Evolving digitalization of vaccine supply chain and cold chain monitoring
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AJ Vaccines AS
- AJ Vaccines AS - Overview
- AJ Vaccines AS - Product / Service
- AJ Vaccines AS - Key offerings
- SWOT
- 15.5 Bharat Biotech Ltd.
- Bharat Biotech Ltd. - Overview
- Bharat Biotech Ltd. - Product / Service
- Bharat Biotech Ltd. - Key offerings
- SWOT
- 15.6 BioKangtai
- BioKangtai - Overview
- BioKangtai - Product / Service
- BioKangtai - Key offerings
- SWOT
- 15.7 Biological E. Ltd.
- Biological E. Ltd. - Overview
- Biological E. Ltd. - Product / Service
- Biological E. Ltd. - Key offerings
- SWOT
- 15.8 Daiichi Sankyo Co. Ltd.
- Daiichi Sankyo Co. Ltd. - Overview
- Daiichi Sankyo Co. Ltd. - Business segments
- Daiichi Sankyo Co. Ltd. - Key news
- Daiichi Sankyo Co. Ltd. - Key offerings
- Daiichi Sankyo Co. Ltd. - Segment focus
- SWOT
- 15.9 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 15.10 Haffkine Bio Pharmaceutical
- Haffkine Bio Pharmaceutical - Overview
- Haffkine Bio Pharmaceutical - Product / Service
- Haffkine Bio Pharmaceutical - Key offerings
- SWOT
- 15.11 Indian Immunologicals Ltd.
- Indian Immunologicals Ltd. - Overview
- Indian Immunologicals Ltd. - Product / Service
- Indian Immunologicals Ltd. - Key offerings
- SWOT
- 15.12 LG Chem Ltd.
- LG Chem Ltd. - Overview
- LG Chem Ltd. - Business segments
- LG Chem Ltd. - Key news
- LG Chem Ltd. - Key offerings
- LG Chem Ltd. - Segment focus
- SWOT
- 15.13 Microgen
- Microgen - Overview
- Microgen - Product / Service
- Microgen - Key offerings
- SWOT
- 15.14 Panacea Biotec Ltd.
- Panacea Biotec Ltd. - Overview
- Panacea Biotec Ltd. - Product / Service
- Panacea Biotec Ltd. - Key offerings
- SWOT
- 15.15 PT Bio Farma
- PT Bio Farma - Overview
- PT Bio Farma - Product / Service
- PT Bio Farma - Key offerings
- SWOT
- 15.16 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.17 Serum Institute of India Ltd.
- Serum Institute of India Ltd. - Overview
- Serum Institute of India Ltd. - Product / Service
- Serum Institute of India Ltd. - Key offerings
- SWOT
- 15.18 Sinovac Biotech Ltd.
- Sinovac Biotech Ltd. - Overview
- Sinovac Biotech Ltd. - Product / Service
- Sinovac Biotech Ltd. - Key offerings
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
